Germany – Pharmaceutical products – Arzneimittelrahmenrabattvertrag gemäß § 130a Abs. 8 bzw. § 130c Absatz 1 des Fünften
DAK-Gesundheit awarded €1 to Swedish Orphan Biovitrum GmbH for Healthcare & Medical in June 2026 — one of 389 awards this buyer has made, in line with its typical award size.
Buying agency
DAK-GesundheitWinning supplier
Swedish Orphan Biovitrum GmbHContract description
Germany – Pharmaceutical products – Arzneimittelrahmenrabattvertrag gemäß § 130a Abs. 8 bzw. § 130c Absatz 1 des Fünften Sozialgesetzbuchs - Aspaveli (Wirkstoff: Pegcetacoplan), ATC L04AJ03
Related awards · DAK-Gesundheit
389 awardsThe buyer's full award list ranked by value, with the winning supplier, date and sector on every row — plus CSV / API export.
- ocds-ted-210283-2024Aktivital GmbH€9.1M10 Apr 2024 Healthcare
- ocds-ted-211590-2024Kraaibeek GmbH€2.5M10 Apr 2024 Healthcare
- ocds-ted-828775-2025news aktuell GmbH€38.0K12 Dec 2025 IT
Other wins · Swedish Orphan Biovitrum GmbH
4 winsThe supplier's complete win history across every buyer it sells to — not just the handful shown here.
- ocds-ted-223295-2026GWQ ServicePlus AG€101 Apr 2026 Healthcare
- ocds-ted-363898-2026IKK classic€128 May 2026 Healthcare
- ocds-ted-719763-2024IKK classic€126 Nov 2024 Healthcare
Premium · full dataset
See the full award context.
Competing bids, award margins and every related contract for DAK-Gesundheit and Swedish Orphan Biovitrum GmbH — one subscription unlocks everything.
Sign Up Free →Free account · cancel anytime · 14-day money-back